CompletedNot Applicable

Cybersickness imAgiNg Olfactory Evocation

France30 participantsStarted 2022-04-13

Plain-language summary

The aim of this study is to, using fMRI, compare brain activations during olfactory imagery induced by different visual supports (words, pictures, colors and colored arrangements) in healthy subjects. This will allow us to choose the best olfactory imagery facilitator and to assess its effect on cybersickness.

Who can participate

Age range

18 Years – 50 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * to be of French nationality who has always lived in metropolitan France; * to be right-handed person; * to be enrolled in a social security plan; * to be able to understand the instructions given; * to have underwent a pre-inclusion medical examination; * to give a written consent; * Person with a strong capacity for olfactory imagination: having obtained a score strictly below 2.5 on the fVOIQ olfactory imagination questionnaire. Exclusion Criteria: * to have an inability to read French; * to be recognized as a synesthete; * to have a professional activity requires intense olfactory activity; * to have a partial or total loss of smell (hyposmia, anosmia); * to have qualitative smell disorders (carcosomia, hyperosmia, phantosmia, parosmia); * to have smell disorders of neurological, post-traumatic or neurodegenerative origin; * to have uncorrected or poorly corrected visual disturbances; * to have vestibular disorder diagnosed; * any contraindication to MR examination (active medical device, ferromagnetic foreign body, pregnancy, morbid obesity, claustrophobia, … ); * subject under a measure of legal protection.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Comparison of cerebral activations between the different supports mediating the olfactory imagination during the execution of the fMRI tasks.

Timeframe: Baseline (J0)

Trial details

NCT IDNCT05308433

SponsorCentral Hospital, Nancy, France

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-07-12

View on ClinicalTrials.gov More Healthy trials